Terminal Hydroxyl-Modified PEG Nanocarriers Evading Antibody Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PEGylated nanocarriers face rapid clearance and complement activation due to pre-existing anti-PEG antibodies in the human body, leading to reduced efficacy and side effects, and animal models do not accurately predict human responses due to differing binding mechanisms and complement activation capabilities.
Innovation Solution
Utilizing terminal hydroxyl-modified PEGylated nanocarriers, such as liposomes, polymer nanoparticles, and lipid nanoparticles, with specific molecular weights and modification ratios to minimize binding with pre-existing anti-PEG antibodies, thereby reducing complement activation and rapid clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEGylated nanocarriers with methoxy end groups are used, then in vivo stability and long circulation characteristics are improved, but pre-existing anti-PEG antibodies rapidly recognize and bind to them, causing complement activation and accelerated clearance by the mononuclear macrophage system
Solution Approach 1:
The patent changes the chemical parameter of the PEG end group from methoxy to hydroxyl. This parameter change fundamentally alters the immunogenicity profile of the PEGylated nanocarrier, allowing it to evade recognition by pre-existing anti-PEG antibodies while maintaining the stabilizing and circulation-prolonging benefits of PEGylation.
2Stability of the object's composition
If PEGylated nanocarriers are used, then in vitro stability is improved, but anti-PEG antibodies accelerate uptake by the mononuclear macrophage system, leading to rapid clearance from blood
Solution Approach 1:
The patent modifies the end group parameter of PEG from methoxy to hydroxyl, which resolves the contradiction between maintaining in vitro stability and avoiding rapid in vivo clearance. The hydroxyl end group preserves the stabilizing properties of PEG while eliminating the antigenic epitopes that trigger antibody-mediated clearance.
3Reliability
If PEGylated nanocarriers are repeatedly injected, then therapeutic efficacy is maintained, but anti-PEG antibodies are produced after repeated injections, causing accelerated clearance and side effects
Solution Approach 1:
The patent changes the PEG end group from methoxy to hydroxyl, which prevents the formation of antigenic complexes that trigger antibody production upon repeated dosing. This parameter change allows for sustained therapeutic efficacy through repeated injections without inducing the ABC phenomenon or adverse immune responses.
Solution Approach 2:
The patent applies preliminary anti-action by pre-modifying the PEG end group to hydroxyl before administration, which proactively prevents the formation of immunogenic complexes that would otherwise trigger antibody production and accelerated clearance upon repeated dosing.
Data Source
Figure 1
Figure 2a~3c
Figure 4a~5d
AI summary
The present invention discloses a method for circumventing pre-existing anti-PEG antibodies in the human body and the use of a terminal hydroxyl-modified PEGylated nanocarrier in the preparation of a drug that circumvents pre-existing anti-PEG antibodies in the human body. The present invention also discloses a terminal hydroxyl-modified PEGylated nanocarrier and a nanoformulation comprising the same. The terminal hydroxyl-modified PEGylated nanocarrier and nanoformulation according to the present invention have a low binding to pre-existing anti-PEG antibodies in the human body, so that they can circumvent being rapidly cleared in the human blood and better exert the therapeutic effect. In addition, the terminal hydroxyl-modified PEGylated nanocarrier and nanoformulation can reduce complement activation by circumventing a binding to pre-existing anti-PEG antibodies in human blood, thereby alleviating side effects such as clinical injection reactions.